As of June 17, 2025, Hansa Biopharma AB (HNSA.ST) reports a Net Margin of -471.20%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Hansa Biopharma AB's Net Margin
Over recent years, Hansa Biopharma AB's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -471.20% |
| 2023-12-31 | -620.25% |
| 2022-12-31 | -395.49% |
| 2021-12-31 | -1618.40% |
| 2020-12-31 | -6901.49% |
This slight downward trend highlights how Hansa Biopharma AB manages its overall profitability and cost control over time.
Comparing Hansa Biopharma AB's Net Margin to Peers
To better understand Hansa Biopharma AB's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Hansa Biopharma AB (HNSA.ST) | -471.20% |
| Nanobiotix SA (NANO.PA) | 586.89% |
| Bioventix PLC (BVXP.L) | 59.51% |
| Basilea Pharmaceutica AG Allschwil (BSLN.SW) | 37.21% |
| Biogaia AB (BIOG B.ST) | 24.70% |
| Swedish Orphan Biovitrum AB (publ) (SOBI.ST) | 14.93% |
Compared to its competitors, Hansa Biopharma AB's Net Margin is about average compared to peers, reflecting typical industry profitability.